📍 Congress Centre – Parco Lido, Riva del Garda
📅 26 – 28 October 2, 2026
🔹 Booth 6
From 26 to 28 October 2026, Sentinel Group will participate in the SIPMeL Congress at the Congress Centre – Parco Lido di Riva del Garda. At booth 6, the Group will present a diagnostic offering designed to address the different stages of the clinical pathway through an integrated approach, from prevention to long-term disease monitoring and treatment response assessment.
During the event, Sentinel Group will showcase a vision built on the integration of complementary expertise, methodologies and technologies. The goal is to support laboratories in generating reliable and actionable data that help guide timely, personalized clinical decisions aligned with patient needs
An approach that connects every stage of the clinical journey
Prevention, diagnostic assessment, specialist investigation and monitoring should not be viewed as separate steps, but as parts of a continuous pathway. At each stage, Laboratory Medicine can contribute to risk identification, clinical characterization, patient stratification and the evaluation of disease progression or therapeutic effectiveness.
Within this continuum, analytical data acquires its true value: not simply as a test result, but as meaningful information that supports physicians and patient management
Focus on gastroenterology, oncology and infectious diseases
Sentinel Group’s presence at SIPMeL 2026 will focus on three key areas of Laboratory Medicine.
In gastroenterology, attention will be directed toward screening programs and intestinal biomarkers that can support prevention, inflammation assessment and evaluation of intestinal function.
In oncology, the diagnostic pathway includes tumor markers, metabolic profiles and solutions dedicated to therapeutic monitoring, contributing to increasingly targeted clinical management.
In infectious diseases, solutions will be presented for viral load testing, transplant patient follow-up, therapeutic drug monitoring of antibiotics and immunosuppressants, and rapid testing applications.
These areas demonstrate how the integration of different technologies can strengthen the laboratory’s ability to address specific clinical needs throughout the entire patient care pathway.
The Group’s expertise
Sentinel Diagnostics will highlight its solutions for clinical chemistry, molecular diagnostics and specialist monitoring. The portfolio includes colorectal cancer screening programs, intestinal biomarkers, molecular applications dedicated to transplant patient management and infectious disease testing, with a strong focus on reliability, speed and result interpretability.
Eureka Lab Division will contribute chromatographic and mass spectrometry technologies applied to therapeutic drug monitoring, toxicology, metabolic profiling and specialist biomarker assessment. These solutions expand the role of the laboratory within precision medicine pathways.
PRIMA Lab will complete the diagnostic pathway with rapid tests designed for prevention and first-line diagnostic guidance, helping to make diagnostics more accessible and widely available within the community.
Together, the combined expertise of Sentinel Diagnostics, Eureka Lab Division and PRIMA Lab enables the Group to provide complementary support, from early risk identification through monitoring of clinical progression and therapeutic response.
Meet us in Riva del Garda
SIPMeL 2026 will provide an opportunity to engage with Laboratory Medicine professionals, sharing perspectives, experiences and solutions dedicated to the evolution of diagnostic pathways.
Sentinel Group looks forward to welcoming you to booth no. 6 in Riva del Garda, from 26 to 28 October, to discover the solutions offered by Sentinel Diagnostics, Eureka Lab Division and PRIMA Lab.